View Older Stories View More Recent Stories

Dec 10, 2025 04:44PM Form SCHEDULE 13G/A Fulcrum Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Dec 7, 2025 08:00AM CellCentric Presents Positive Phase 2 Dose Optimization Data for Inobrodib in Multiple Myeloma at ASH Annual Meeting
Dec 4, 2025 08:00AM Trinity Capital Inc. Provides Equipment Financing to Sortera Technologies to Scale AI-Powered Upcycling Innovation
Dec 3, 2025 04:22PM Form SCHEDULE 13G Benitec Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Dec 3, 2025 08:00AM TRIANA Biomedicines Announces Oversubscribed $120M Series B Financing to Advance its Molecular Glue Degrader Pipeline
Nov 21, 2025 05:32PM Exploring the Next Era of CGT and Unlocking Limitless Possibilities: The GenScript Biotech Global Forum London 2025 Wraps Up
Nov 20, 2025 10:00AM Navigator Medicines Completes Last Participant Last Visit (LPLV) in Phase 1b Trial of NAV-240, an OX40L and Anti-TNFα Bispecific Antibody for Autoimmune Diseases
Nov 20, 2025 08:30AM Sortera Scales Solution to the Mixed Aluminum Problem with $45 Million in Funding and New Tennessee Facility
Nov 17, 2025 04:44PM Form SCHEDULE 13D Evommune, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 17, 2025 04:39PM Form SCHEDULE 13D/A Cidara Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 17, 2025 09:15AM Bambusa Therapeutics Announces Completion of Series A-2 Financing to Accelerate Next-Generation Bispecific Programs
Nov 17, 2025 08:15AM Halda Therapeutics Announces Acquisition by Johnson & Johnson
Nov 17, 2025 08:00AM Artios Announces Oversubscribed $115 Million Series D Financing to Accelerate Clinical Programs in Indications of High Unmet Need
Nov 17, 2025 08:00AM T-knife Therapeutics Files Clinical Trial Application for Phase 1 ATLAS Trial for TK-6302, a Supercharged PRAME-targeted T Cell Receptor Therapy
Nov 17, 2025 05:53AM Adcytherix Powers Ahead: Technology and Team in Place to Deliver Strategy and Build an ADC Powerhouse
Nov 14, 2025 06:13PM Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 14, 2025 04:26PM Form SCHEDULE 13G/A Unicycive Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 14, 2025 04:26PM Form SCHEDULE 13G/A Tourmaline Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 14, 2025 04:25PM Form SCHEDULE 13G/A Taysha Gene Therapies, Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 14, 2025 04:23PM Form SCHEDULE 13G/A RxSight, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 14, 2025 04:21PM Form SCHEDULE 13G/A Monopar Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 14, 2025 04:20PM Form SCHEDULE 13G/A Edgewise Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 14, 2025 04:18PM Form SCHEDULE 13G/A Dyne Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 14, 2025 04:17PM Form SCHEDULE 13G/A Avidity Biosciences, Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 14, 2025 04:17PM Form SCHEDULE 13G/A Dianthus Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 14, 2025 04:16PM Form SCHEDULE 13G/A Avalo Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 14, 2025 04:06PM Form 13F-HR RA CAPITAL MANAGEMENT, For: Sep 30
Nov 14, 2025 10:23AM LAST CALL: Join Nobel Laureate & Global Leaders to Explore the Next Era of Cell & Gene Therapy in London
Nov 13, 2025 08:47PM Form SCHEDULE 13D/A Wave Life Sciences Ltd. Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 12, 2025 08:27PM Form SCHEDULE 13G BIOCRYST PHARMACEUTICALS Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 12, 2025 04:26PM Form 4 Evommune, Inc. For: Nov 07 Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 10, 2025 04:40PM Form SCHEDULE 13D/A Cidara Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 10, 2025 07:19AM Galecto completes Damora acquisition with $285 million funding round
Nov 10, 2025 07:00AM Galecto Announces Acquisition of Damora Therapeutics
Nov 10, 2025 06:00AM ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)
Nov 7, 2025 04:59PM Form SCHEDULE 13D/A Sionna Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 7, 2025 04:47PM Form SCHEDULE 13D/A LENZ Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 7, 2025 09:00AM T-knife Therapeutics Presents Preclinical Data on PRAME-Targeted TK-6302 Highlighting its Potential as a Promising, Category-leading Therapy at the Society for Immunotherapy of Cancer (SITC) Annual Me
Nov 6, 2025 04:33PM RANI Therapeutics secures $1.085 billion Chugai deal and $60.3 million funding
Nov 6, 2025 04:30PM Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update
Nov 6, 2025 04:30PM Form SCHEDULE 13D/A Werewolf Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 6, 2025 04:05PM Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates
Nov 6, 2025 07:01AM Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Nov 6, 2025 07:00AM C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Nov 4, 2025 08:00AM Azalea Therapeutics Launches with $82 Million Financing to Redefine Precision Genomic Medicines by Engineering Cells Directly Inside Each Patient
Nov 3, 2025 04:43PM Form SCHEDULE 13D/A 89bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 3, 2025 09:00AM CellCentric to Host Investor Event and Present Dose Optimization Data from Phase 2 Study of Inobrodib for Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting
Oct 30, 2025 06:42PM Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Oct 30, 2025 04:36PM Form SCHEDULE 13G Rani Therapeutics Holdin Filed by: RA CAPITAL MANAGEMENT, L.P.
Oct 30, 2025 08:00AM T-knife Therapeutics Announces Four Upcoming Data Presentations on PRAME-Targeted TK-6302 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
View More Recent Stories View Older Stories